Medicilon Logo
|
search icon search icon language icon contact icon menu icon
Medicilon Logo
|
search icon close search icon language icon contact icon menu icon
CN
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Medicilon Events
News and Events

Medicilon Events

Hot information:
Medicilon Appoints Dr. Liu Jian as President of Drug Discovery Division| Medicilon FTE services & FFS services - flexible and efficient cooperation model| Medicilon and Wuhan biolake successfully organized a biopharmaceutical salon
Jul 10,2024
Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development
Medicilon announced that its wholly-owned subsidiary, Medicilon Preclinical Research (MRP), has officially signed a collaboration agreement with Hetuo Innovation (Hetuo) in the fields of neurological disorders, ophthalmic diseases, and cardiovascular system drugs​.
More
Medicilon Preclinical Research and Hetuo Innovation are joining hands to co-create and innovate in drug development
Jul 10,2024
Six consecutive years! Medicilon once again tops the '2023 China CXO Enterprise Top 20 List'
Medicilon, with its outstanding R&D capabilities and continuous spirit of innovation, has once again topped the 2023 China CXO (including CDMO) Enterprise Top 20 List. This is the sixth consecutive year that Medicilon has received this honor.
More
Six consecutive years! Medicilon once again tops the '2023 China CXO Enterprise Top 20 List'
Jul 02,2024
For three consecutive years! Medicilon has been honored with the "Top Ten Drug Innovation Service Institutions of the Year" award at the 4th Pharmaceutical Innovation Awards.
Medicilon was honored with the "Top Ten Drug Innovation Service Institutions of the Year" at the 4th Pharmaceutical Innovation Awards for its innovative capabilities and service quality in the field of biopharmaceutical preclinical R&D services.
More
For three consecutive years!  Medicilon has been honored with the "Top Ten Drug Innovation Service Institutions of the Year" award at the 4th Pharmaceutical Innovation Awards.
Jul 02,2024
Medicilon assists Suzhou Jingye Medicine & Chemical in a strong transformation, listen to Weidong Yuan share how to open up a new chapter in the API field.
Suzhou Jingye successfully obtained the "Notice of Approval for Chemical API Marketing Application" issued by the NMPA for its raw material of Clomipramine hydrochloride. Meanwhile, as a partner of Jingye, Medicilon has provided services such as API process development and solvent substitution.
More
Medicilon assists Suzhou Jingye Medicine & Chemical in a strong transformation, listen to Weidong Yuan share how to open up a new chapter in the API field.
Jun 20,2024
Medicilon AI Drug Discovery Service Platform: An Efficient Booster for New Drug Development
Medicilon's AI technology service platform can provide protein structure prediction and simulation, binding site discovery, information extraction and cleansing, as well as customized project database construction, meeting diverse needs of researchers.
More
Medicilon AI Drug Discovery Service Platform: An Efficient Booster for New Drug Development
Jun 20,2024
Medicilon Interview - Smart Drug Development is Inevitable: Dr. Feng Ren Talks Fearless Advancements in AI Pharmaceuticals
Medicilon is honored to invite Dr. Feng Ren, the joint CEO and Chief Scientific Officer of Insilico Medicine, to discuss and interpret the developments and trends of AI in new drug research and development.
More
Medicilon Interview - Smart Drug Development is Inevitable: Dr. Feng Ren Talks Fearless Advancements in AI Pharmaceuticals
Jun 13,2024
Medicilon Interview - Sungening Biological has successfully authorized collaboration, and Dr. Chenguang Yuan elaborated on the market trends and innovations in antifungal drugs
Sungening Biological (Sungening) has successfully obtained an implicit permission from the National Medical Products Administration for clinical trials (acceptance number: CXHL2400203) for its first innovative drug, SG1001.
More
Medicilon Interview - Sungening Biological has successfully authorized collaboration, and Dr. Chenguang Yuan elaborated on the market trends and innovations in antifungal drugs
Jun 12,2024
Medicilon Nucleic Acid Drug Preclinical Evaluation Services
Medicilon has accumulated profound accumulation in the field of nucleic acid drug research and development, and has comprehensive preclinical research capabilities: strong research strength in drug synthesis, modification and delivery systems to ensure drug stability and activity.
More
Medicilon Nucleic Acid Drug Preclinical Evaluation Services
May 21,2024
Medicilon honored with the 'Best Client Satisfaction Pharmaceutical CRO' at the 2024 VBEF."
On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources.
More
Medicilon honored with the 'Best Client Satisfaction Pharmaceutical CRO' at the 2024 VBEF."
May 16,2024
Empowering API Quality Enhancement! Medicilon Received the 'Best Collaboration Award' from Jingye Medicine & Chemical Co., Ltd
Recently, Medicilon is honored to have received a thank-you letter from Jingye Medicine & Chemical Co., Ltd (Jingye Medicine) and was awarded the "Best Collaboration Award".
More
Empowering API Quality Enhancement! Medicilon Received the 'Best Collaboration Award' from Jingye Medicine & Chemical Co., Ltd
May 16,2024
Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"
Medicilon USA Corp. (Medicilon) stood out with its cutting-edge innovative technology and excellent service capabilities, and won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year".
More
Winning for the third time in a row! Medicilon won the "Pharmaceutical Innovation Award - Top Ten Drug Innovation Service Institutions of the Year"
May 07,2024
Technological Innovation, Authority Reaffirmed! Medicilon was awarded the "2023 Shanghai Science and Technology Little Giant Enterprise"
Recently, the Shanghai Science and Technology Commission officially issued the "Notice on the Announcement of the List of 2023 Shanghai Science and Technology Little Giants (Including Cultivation) Enterprises". Medicilon was recognized as one of the 2023 Shanghai Science and Technology Little Giants Company.
More
Technological Innovation, Authority Reaffirmed! Medicilon was awarded the "2023 Shanghai Science and Technology Little Giant Enterprise"